Corrected: Israel's Entera Bio Q2 net loss widens

Entera Bio

07/08/2026 21:31

Corrects period in Key Details to Q2, from H1

Overview
Israel oral peptide developer reported no revenue for Q2 2026
Company's net loss widened due to higher R&D and non-cash warrant remeasurement
Oversubscribed $275 mln private placement expected to fund Phase 3 EB613 and operations into 2030

Outlook
Entera plans to start EB613 Phase 3 study in late 2026, topline data expected H2 2028
Company expects to file IND for EB612 in first half of 2027
Recent $275 mln private placement expected to fund operations through EB613 NDA submission and into 2030

Result Drivers
R&D SPENDING - Higher research and development expenses driven by EB613 Phase 3 preparation and OPKO collaboration activities
WARRANT REVALUATION - Net loss increased due to non-cash fair value remeasurement of pre-funded warrants from April 2026 private placement

Company press release: ID:nGNX1JNwpG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.14
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Entera Bio Ltd is $9.00, about 219.1% above its August 6 closing price of $2.82

Reuters Recommended Reads
Aug 6 - Definium Therapeutics Q2 net loss widens on higher warrant costs
Aug 6 - Precision BioSciences Q2 net loss widens on warrant liability charge
Aug 6 - Ireland's GH Research Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)